Remix CEO Peter Smith and COO Heather Wasserman

J&J jumps on the RNA band­wag­on, ink­ing dis­cov­ery deal with Remix for a po­ten­tial­ly new class of drugs

Among the hottest fields in drug dis­cov­ery, RNA ther­a­peu­tics have tak­en the world of Big Phar­ma by storm. J&J, not nor­mal­ly the tip of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.